Successfully developed China's 1st fast-acting human insulin analog - Prandilin^® (Lispro)

Successfully developed China's 1st long-acting human insulin analog - Basalin^® (Glargine)

Successfully developed China's 1st premixed human insulin analog - Prandilin ^® 25 (Lispro 25R)

Company was restructured and renamed to“Gan & Lee Pharmaceuticals ”

Patents were obtained for the Molecular Chaperone Technology in China and PCT patent was obtained in the US

Received production approval and GMP certificate for Basalin^® from the NMPA (before CFDA)

Basalin^® went on sale

Basalin^® entered the international market, including Egypt, Pakistan, Mexico, etc.

The company's sales revenue exceeded RMB100 million

China's 1st independently developed insulin injection pen-Insulin Pen was launched

The company completed the shareholding transformation and its name was changed to “Gan & Lee Pharmaceuticals”

China's 1st premixed human insulin analog Prandilin^® 25 was launched

Founded Gan & Lee Pharmaceuticals USA

Completed the construction of the new insulin analog manufacturing plant in Beijing

Insulin glargine was allowed by the FDA to proceed with Phase I clinical study in US

Basalin passed Europe's QP inspection and was allowed to proceed with Phase I and Phase III clinical trials in Europe

Gan & Lee attended the 78th American Diabetes Annual Conference (ADA) as the first Chinese pharmaceuticals to attend the conference

Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis on biosimilar versions of insulins used in patients with type 1 and type 2 diabetes

Recombinant insulin lispro was allowed by the FDA & European Medicines Agency to proceed with Phase I and Phase III clinical trials in the US and Europe

Gan & Lee was Initially listed on the A-share index on the Shanghai Stock Exchange

Aspart was approved for listing in China

Started the construction of Gan & Lee Linyi Production Base

Phase 1 Drug Candidate GLR2007 has been Granted Orphan Drug Designation and Fast Track Designation by the US FDA

In the sixth batch of the national centralized drug-procurement program (insulin special) , all six products of Gan & Lee Company won the bid with high ranking

Gan & Lee Announces New Partnership with the International Diabetes Federation

The clinical trial application of GZR18, a GLP-1 RA, is approved by Chinese National Medical Products Administration

EMA granted orphan drug designation for GLR2007

Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals is listed

Insulin glargine completed overseas phase III clinical trial

First Patient Dosed in Phase II Clinical Trials of the company’s investigational drug GLP-1RA (GZR18) in China and the first subject has been dosed in the U.S

Gan & Lee's self-developed Class 1.1 new drug GZR101 has initiated Phase I clinical trials and the first subject has been dosed in China

The first subject had been dosed in a Phase I clinical trial of GZR4 (a novel, ultra-long-acting insulin analog independently developed by company ) in China, and FDA has allowed the IND to go forward allowing patients to be treated in the protocol submitted with the IND

Received the approval for the registration of Sitagliptin phosphate tablets issued by the NMPA

The submission of Biologics License Application(BLA) of the three insulin products, insulin glargine, lispro, and aspart, has been accepted by the US FDA and EMA as filed application and entered the substantive review stage

NMPA Issued IND Clearance for Gan & Lee’s First Monoclonal Antibody GLR1023 Injection

Gan & Lee company won the bidding for all six of its products according to the announcement of insulin successor procurement results

Gan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial